Latest News & Features
Big Pharma
For generic drug makers, previous bad behaviour may affect new litigation, especially when it comes to injunctions, as Bethan Hopewell and Geraldine Quinn explain. 16 October 2013
Asia
LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world. 16 October 2013
Biotechnology
When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look. 16 October 2013
Biotechnology
The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe. 16 October 2013
Americas
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains. 16 October 2013
Americas
Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach. 30 September 2013
Biotechnology
With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit. 30 September 2013
Big Pharma
The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products. 30 September 2013
Asia
There has been much debate about whether there is a global deterioration of IP, and many commentators
would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India. 31 August 2013
Americas
In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP. 31 August 2013